Effect of cheese containing Lactobacillus delbrueckii subsp. Lactis CRL 581 on blood pressure in prehypertensive and stage 1 hypertensive subjects
Author
Salazar,Martín
Malpeli,Agustina
Hebert,Elvira
Cravero,Ricardo
Espeche,Walter
Sisnieguez,Cecilia Leiva
Stavile,Rodolfo N.
March,Carlos
Sisnieguez,Carlos Leiva
Tavella,Marina
Disalvo,Liliana
Fasano,Victoria
Magrini,Graciano
Visentin,Dimas
Taranto,M. Pía
González,Horacio F.
Abstract
ABSTRACT Hypertension is one of the main risk factors for cardiovascular disease. Functional foods containing bioactive peptides have been proposed as a strategy to decrease blood pressure (BP) in subjects under no pharmacological treatment. The aim of this study was to compare the effect of low-sodium, low-fat (LSLF) cheese and LSLF cheese containing Lactobacillus delbrueckii subsp. lactis CRL 581 (LSLF581) on BP in pre-hypertensive and stage 1 hypertensive subjects. Sixty-one pre-hypertensive and stage 1 hypertensive subjects assigned to one of twos (LSLF, n= 29 and LSLF581, n= 32) participated in this 12-month prospective, randomized, double-blind, crossover trial. Twenty-four h ambulatory BP monitoring was performed at the beginning and at the end of each four-week study period. Systolic and diastolic BP decreased in both study groups, but differences between groups were not significant (systolic, −1.78 and −0.2 mmHg; diastolic, −1.54 and −0.42 mmHg in LSLF581 and LSLF, respectively). Although our results could not support a BP lowering effect of LSLF581, small BP reductions could favorably prevent cardiovascular disease development.